Additionally, the potential nephroprotective effects of SGLT2 inhibitors in systemic lupus erythematosus (SLE) are supported by preliminary findings from animal models and small-scale observational studies. This evidence concerns the gene SLC5A2 and systemic lupus erythematosus.